行情

NLNK

NLNK

NewLink Genetics
NASDAQ

实时行情|Nasdaq Last Sale

1.720
+0.200
+13.16%
已收盘, 17:24 12/09 EST
开盘
1.580
昨收
1.520
最高
1.815
最低
1.520
成交量
107.90万
成交额
--
52周最高
2.270
52周最低
1.130
市值
6,418.02万
市盈率(TTM)
-1.4158
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

NLNK 新闻

  • Edited Transcript of NLNK earnings conference call or presentation 6-Nov-19 1:30pm GMT
  • Thomson Reuters StreetEvents.11/12 23:11
  • NewLink Genetics Announces European Commission Grant of Conditional Marketing Approval for Ebola Vaccine V920 (ERVEBO®)
  • GlobeNewswire.11/12 14:00
  • NewLink Genetics Corporation (NLNK) Management on Q3 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript.11/08 18:04
  • NewLink Genetics reports Q3 results
  • seekingalpha.11/06 18:12

更多

所属板块

生物技术和医学研究
+0.51%
制药与医学研究
+0.23%

热门股票

名称
价格
涨跌幅

NLNK 简况

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company's portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute Cellular Immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells. Its additional HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma, respectively. Additionally, it has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system's tolerance to cancer.
展开

Webull提供NewLink Genetics Corp的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。